MedTrace Logo

ETHAN - ET for Male BC

NCT05501704 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-30

No results posted yet for this study

Summary

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer.

The drugs used in this study are:

* Tamoxifen
* Anastrozole
* Degarelix
* Abemaciclib

Conditions

Interventions

DRUG

Tamoxifen

Taken orally

DRUG

Anastrozole

Taken orally

DRUG

Degarelix

Subcutaneous (under the skin) injection

DRUG

Abemaciclib

Taken orally

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Translational Breast Cancer Research Consortium (TBCRC)

    collaborator UNKNOWN

  • Jose Pablo Leone

    lead OTHER

Principal Investigators

  • Jose Pablo Leone, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-11
Primary Completion
2027-04-01
Completion
2036-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05501704 on ClinicalTrials.gov